A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Man Fung YuenChi-Yi ChenChun-Jen LiuWen-Juei JengMagdy ElkhashabCarla S CoffinWon KimSusan GreenbloomAlnoor RamjiYoung Suk LimYoon Jun KimScott K FungDong Joon KimJeong Won JangKwan Sik LeeRadhakrishnan P IyerChelsea MacfarlaneKathy JacksonStephen A LocarniniHenry Lik Yuen ChanNezam H AfdhalPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
Twelve-week Inarigivir up to 200 mg dose was associated with a reduction of HBV DNA, HBV RNA and antigen levels. A trend for greater HBsAg reduction was observed in Inarigivir pre-treated patients after switching to tenofovir.
Keyphrases
- hepatitis b virus
- open label
- end stage renal disease
- newly diagnosed
- phase iii
- chronic kidney disease
- liver failure
- ejection fraction
- phase ii
- clinical trial
- placebo controlled
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- single molecule
- squamous cell carcinoma
- study protocol
- cell free
- circulating tumor
- circulating tumor cells